Pfizer and BioNTech's Coronavirus Vaccine Approved in Europe
Fresh off receiving its crucial emergency use authorization (EUA) in the U.S., Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) coronavirus vaccine has received similar approval in Europe.
Both companies announced Monday that their BNT162b2 -- which will also be known in Europe under the brand name Comirnaty -- has received conditional marketing authorization (CMA) from the European Commission (EC) for patients aged 16 and older.
This is roughly the equivalent of the American EUA in that it's the culmination of a fast-track approval process for a vaccine or drug that combats acute healthcare threats such as the coronavirus. The CMA is valid for one year.
Source Fool.com
